New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:01 EDTNYMXNymox reports update on nerve sparing in men treated with NX-1207
Nymox Pharmaceutical reports new data supporting the positive sexual functional preservation profile of NX-1207, the company's lead compound in Phase 3 development for the treatment of prostate enlargement and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments. The nerve-sparing findings are consistent with results from earlier studies which have shown evidence of sexual functional preservation in men after NX-1207 treatment, including 1) patient reports of no significant new clinical sexual problems, 2) no change in blood testosterone levels, and 3) sexual function questionnaire data showing no sexual side effects from NX-1207 treatment.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:03 EDTNYMXNymox says Phase 2 NX03-0040 study successfully met pre-determined endpoints
Nymox Pharmaceutical Corporation announced results from the completion of the company's U.S. 40 month localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate. The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.The clinical trial commenced in February 2012 at 28 U.S. investigational clinical trial sites and enrolled 147 patients with low grade localized prostate cancer. The study lasted 40 months overall from the first patient randomized to the last patient 18 month endpoints. "These results demonstrate that a single targeted office injection of fexapotide has led to statistically significant improvement in outcomes with much less surgery or radiotherapy required after 18 months. This means a reduction in patient discomfort, and a reduction in permanent side effects and life changes when the more invasive treatments are required," said Paul Averback, CEO of Nymox.
February 4, 2016
11:19 EDTNYMXNymox announces private placement equity investment of $2.1M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use